Loading…
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-284M | $-256M | $-233M | -28.3% | - | - |
| 2024 | $0M | $-217M | $-182M | $-172M | -25.4% | - | - |
| 2023 | $0M | $-93M | $-84M | $-75M | -22.1% | - | - |
| 2022 | $0M | $-31M | $-40M | $-16M | -28.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 30.73 | 93 | 216.87 | 285.60 |
| Operating Income | -30.73 | -93 | -216.87 | -285.60 |
| EBITDA | -30.64 | -93 | -216.68 | -284.18 |
| EBIT | -30.64 | -93 | -216.87 | -285.60 |
| Pretax Income | -39.78 | -83.98 | -182.13 | -255.56 |
| Tax Provision | 0 | 0 | 0.02 | 0.28 |
| Net Income | -39.78 | -83.98 | -182.15 | -255.84 |
| Net Income Common Stockholders | -39.78 | -83.98 | -182.15 | -255.84 |
| Total Expenses | 30.73 | 93 | 216.87 | 285.60 |
| Interest Expense | 9.15 | 0 | 0 | 0 |
| Interest Income | 0.09 | 9.02 | 34.74 | 30.03 |
| Research And Development | 27.79 | 68.42 | 167.87 | 214.71 |
| Selling General And Administration | 2.94 | 24.58 | 49.01 | 69.75 |
| Normalized EBITDA | -30.64 | -93 | -216.68 | -284.18 |
| Normalized Income | -39.78 | -83.98 | -182.15 | -255.84 |
| Basic EPS | -1.46 | -3.36 | -3.30 | 0 |
| Diluted EPS | -1.46 | -3.36 | -3.30 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0.21 |
| Net Income From Continuing Operation Net Minority Interest | -39.78 | -83.98 | -182.15 | -255.84 |
| Reconciled Depreciation | 0 | 0 | 0.19 | 1.42 |
| Net Interest Income | -9.06 | 9.02 | 34.74 | 30.03 |
| Net Income From Continuing And Discontinued Operation | -39.78 | -83.98 | -182.15 | -255.84 |
| Total Operating Income As Reported | -30.73 | -93 | -216.87 | -285.60 |
| Diluted Average Shares | 27.25 | 25.01 | 55.19 | 0 |
| Basic Average Shares | 27.25 | 25.01 | 55.19 | 0 |
| Diluted NI Availto Com Stockholders | -39.78 | -83.98 | -182.15 | -255.84 |
| Net Income Including Noncontrolling Interests | -39.78 | -83.98 | -182.15 | -255.84 |
| Net Income Continuous Operations | -39.78 | -83.98 | -182.15 | -255.84 |
| Net Non Operating Interest Income Expense | -9.06 | 9.02 | 34.74 | 30.03 |
| Interest Expense Non Operating | 9.15 | 0 | 0 | 0 |
| Interest Income Non Operating | 0.09 | 9.02 | 34.74 | 30.03 |
| Depreciation Amortization Depletion Income Statement | 0 | 0 | 0 | 1.13 |
| Depreciation And Amortization In Income Statement | 0 | 0 | 0 | 1.13 |
| Depreciation Income Statement | 0 | 0 | 0 | 1.13 |
| General And Administrative Expense | 2.94 | 24.58 | 49.01 | 69.75 |
| Other Gand A | 1.30 | 24.58 | 18.70 | 19.12 |
| Salaries And Wages | 1.64 | 12.58 | 30.30 | 50.64 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Apogee Therapeutics, Inc.this co. | APGE | $7.3B | - | 6.21 | -28.3% | -17.34 |
| Vaxcyte, Inc. | PCVX | $8.3B | - | 2.80 | -28.5% | -7.50 |
| Nuvalent, Inc. | NUVL | $7.8B | - | 6.21 | -34.1% | - |
| Cytokinetics, Incorporated | CYTK | $7.4B | - | -11.11 | 119.0% | -13.11 |
| ImmunityBio, Inc. | IBRX | $7.2B | - |
| -14.06 |
| 70.3% |
| -32.25 |
| HealthEquity, Inc. | HQY | $6.9B | 33.12 | 3.29 | 10.2% | 15.69 |
| Arcellx, Inc. | ACLX | $6.7B | - | 16.56 | -56.9% | -25.69 |
| Kymera Therapeutics, Inc. | KYMR | $6.7B | - | 4.20 | -19.7% | -17.38 |
| Spyre Therapeutics, Inc. | SYRE | $6.2B | - | 10.05 | 0.0% | - |
| Peer Median | - | 33.12 | 3.74 | -9.9% | -15.25 | |